Skip to main content
. Author manuscript; available in PMC: 2017 Dec 5.
Published in final edited form as: Nat Biomed Eng. 2017 Jun 5;1:0078. doi: 10.1038/s41551-017-0078

Table 2.

Summary of the pharmacokinetic properties of GLP1 and GLP1-ELP fusions

Construct t1/2,elim#
(h)		 t1/2,biol#
(h)		 tmax
(h)		 Cmax
(nM)		 Delivery
Duration
(d)		 AUC
(nM×h)		 CL
(mL/h)		 Bioavailability
(%)
GLP1 0.08 (0.06 to 0.12) 4.7 (3.4 to 7.0) 0.75 484 ± 26% < 1 4,418 ± 618% 2.88 ± 0.48 98.1 ± 22.8
GLP1-ELPsol 5.7 (3.8 to 11.4) 16.9 (14.5 to 20.3) 6 2,123 ± 49 3 56,451 ± 1,782 0.23 ± 0.01 38.6 ± 0.8
GLP1-ELPopt 6.9 (5.3 to 9.8) 45.2 (33.7 to 68.3) 6 295 ± 13 10 29,872 ± 1,069 0.42 ± 0.10 33.4 ± 21.0
#

Values reported are the mean with 95% CI range in parentheses.

%

Cmax and AUC for GLP1 are lower than the values for GLP1-ELP because of the lower treatment dose used for free peptide (50 nmol/kg) versus GLP1-ELP fusion (700 nmol/kg).